undamentalytics Newsletter
Sign in

Meiragtx Holdings plc (MGTX) stock

Add to watchlist

Add holding +

NASDAQ: MGTX Nasdaq Biotechnology Next results ~November 12, 2026

A Fundamentals grade

Meiragtx Holdings plc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$4.8

Valuation models combined (3)

Base case. Range ~$2.2–$7.7. Weighted average of 3 models (growth cash-flow model, price-to-earnings vs peers, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Meiragtx Holdings plc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 10 sales by directors and officers, last 12 monthsInsider trades
  • Funds118 adding, 34 cuttingOf 34 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Meiragtx Holdings files

Where Meiragtx stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $398m, up 948.3% on a year earlier, faster than the 131.1% growth a quarter earlier. That growth ranks 10 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to 2.6% from -353.3% a year earlier. Operating margin widened to 46.3% from -416.5%. The diluted share count is up 8.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades A. It passes 4 of our 6 financial-health checks. Our revenue-to-maturity cash-flow model value is $41.32 a share, against a share price of $9.71.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Meiragtx Holdings plc's trailing-twelve-month revenue grew 948.3% year on year, with a free-cash-flow margin of 2.6%. Where it stands out: operating margin of 46.3% ranks 5 of 175 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 948.3% (+817.2pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 948.3% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 817.2 points higher than a quarter earlier.
  • High operating margin. 46.3% of revenue is left as operating profit, against a median of -189.4% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 462.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 8.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 58% and a beta of 1.6 against the S&P 500.
  • Weak cash conversion. Free cash flow was 13% of net income over the last 12 months.
  • Short interest rising. Shares sold short rose 60% in a month to 9.3% of tradable shares.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
$2.52 against an average estimate of -$0.42: beat by 697.3%
Revenue
$321m, up 8608.6% on a year earlier
Share reaction
+4.3% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.47

Meiragtx Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.1%
  • 1 week+0.2%
  • 1 month-12.7%
  • This year+17.2%
  • 1 year+7.9%
  • 5 years-53.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$398M
Operating margin
46.3%
Net margin
19.9%
EPS (TTM, diluted)
$0.94

Growth

Revenue growth
+948.3%
Change in growth rate
+817.2 pts
Share count change
+8.6%

Cash

Free cash flow (TTM)
$10.5M
FCF margin
2.6%
Stock pay % of revenue
4.8%

Earnings

Last results
August 13, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results
  3. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Meiragtx Holdings plc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Meiragtx Holdings plc as an operating company, with every model that fits that kind of business. Cost of equity 10.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.19 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.0 ~$3.1–$4.5 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$7.7 ~$6.0–$18 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.2 ~$2.2–$8.3 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$26 ~$22–$32 Left out: far from the other models (more than 3x away from their median)
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$4.8 ~$2.2–$7.7 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Meiragtx Holdings plc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$20.02$15.14$23.74$6.52$7.02$6.09$7.95$9.32
Market value$664m$571m$1.0bn$295m$397m$425m$639m$786m
+ Net debt (− = net cash)−$227m−$210m−$137m−$44m−$57m−$30m$8m−$43m
Enterprise value$437m$362m$911m$250m$339m$395m$648m$743m
Multiples
Price / sales 49.9x36.7x27.8x18.5x28.3x12.8x7.9x2.0x
Price / earnings ———————9.9x
Price / free cash flow 60.0x——————75.1x
EV / EBITDA ———————3.8x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Meiragtx Holdings's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -34.9% of total assets over 9 years.

  • Durability 10 / 20

    Operating margin has been a median -345.1%; its worst year was -2083.2%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -403.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 103.9% over five years; stock-based pay has been a median 95.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $7m and EPS of −$0.47 (range −$0.53 to −$0.38) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.51 +136% $337m +314%
Next −$1.52 −399% $67m −80%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −134.8% on 90 days ago. In the last 30 days, 2 analysts raised Meiragtx Holdings plc's forecast and 0 cut it.

Consensus EPS forecast Meiragtx Holdings plc, last 90 days
−$2.00 −$1.00 $0.00 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.47 Current fiscal year, 60 days ago: −$1.44 Current fiscal year, 30 days ago: $0.51 Current fiscal year, 7 days ago: $0.51 Current fiscal year, Now: $0.51 $0.51 Next fiscal year, 90 days ago: −$1.39 Next fiscal year, 60 days ago: −$1.37 Next fiscal year, 30 days ago: −$1.39 Next fiscal year, 7 days ago: −$1.39 Next fiscal year, Now: −$1.52 −$1.52

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.47−$1.39
60 days ago −$1.44−$1.37
30 days ago $0.51−$1.39
7 days ago $0.51−$1.39
Now $0.51−$1.52

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.42 $2.52 +697.3%
Mar 2026 −$0.45 −$0.57 −27.4%
Dec 2025 −$0.62 $0.19 +130.7%
Sept 2025 −$0.49 −$0.62 −26.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026

No numeric guidance in Meiragtx Holdings plc's latest earnings release (filed August 13, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

8 analysts, Oct 2026
Buy788%
Hold113%
Sell00%

Monthly trend

  1. Oct 20262518
  2. Sep 2026257
  3. Aug 2026257

Counts of recommendations published by analysts covering Meiragtx Holdings plc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.3%
of tradable shares
Days to cover
5.84
at average volume
Short interest, 1 month
+60%
to October 15, 2026
Held by institutions
71%
of shares
Held by insiders
16.3%
of shares
Employees
393
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +2.6%

$9.08 on October 31, 2025 to $9.32

ThenNowEffect
Revenue (last 12 months) $38m $398m +948.3%
P/S multiple 18.6x 2.0x −89.4%
Share count 78m 84m −7.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MGTX+57%−73%+8%−13%+31%+17%
Industry peers (median)−36%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MGTX50%33%42%50%58%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MGTX−34%−76%−58%−47%−44%−39%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 8, 2018: 88% from July 9, 2019 to October 24, 2023. Getting back needed a 734% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$6.99 – $14.97
From 52-week high
−37.7%
vs 50-day average
−19.7%
vs 200-day average
−9.7%
Volatility (1 year)
58%
Beta vs S&P 500
1.62

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±5.5%
After a week
6 up, 6 down
typical move ±10.1%
After a month
3 up, 9 down
typical move ±9.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +4.3% +0.5% +12.2% −0.6%
May 14, 2026 −5.7% −0.4% −4.8% −2.2%
March 26, 2026 0.0% −3.5% +20.5% +19.8%
November 13, 2025 −5.4% −1.7% −14.2% +2.8%
August 14, 2025 −2.0% −0.2% −5.9% −12.1%
May 13, 2025 −17.5% +0.8% −2.1% +17.3%
March 13, 2025 +21.5% +0.7% +19.3% −18.9%
November 13, 2024 −0.3% −0.6% −12.6% −8.1%
August 12, 2024 −3.4% +1.7% −1.4% −4.8%
May 9, 2024 −1.4% +0.7% +10.5% −6.6%
March 14, 2024 0.0% −0.9% +1.7% −13.9%
November 14, 2023 +4.7% +2.2% +15.9% −1.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Meiragtx Holdings plc in five measures

Fundamentals grade A
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Meiragtx Holdings plc
$0 $100M $200M $300M $400M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $6.7M Revenue (TTM), FY23 Q4: $14M Revenue (TTM), FY24 Q1: $11.4M Revenue (TTM), FY24 Q2: $8.1M Revenue (TTM), FY24 Q3: $13.9M Revenue (TTM), FY24 Q4: $33.3M Revenue (TTM), FY25 Q1: $34.5M Revenue (TTM), FY25 Q2: $37.9M Revenue (TTM), FY25 Q3: $27.4M Revenue (TTM), FY25 Q4: $81.4M Revenue (TTM), FY26 Q1: $79.8M Revenue (TTM), FY26 Q2: $397.5M $397.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $6.7M
FY23 Q4 $14M
FY24 Q1 $11.4M
FY24 Q2 $8.1M
FY24 Q3 $13.9M
FY24 Q4 $33.3M
FY25 Q1 $34.5M
FY25 Q2 $37.9M
FY25 Q3 $27.4M
FY25 Q4 $81.4M
FY26 Q1 $79.8M
FY26 Q2 $397.5M
Revenue growth, TTM YoY Meiragtx Holdings plc
-500% 0% 500% 1000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -84.2% Revenue growth, TTM YoY, FY23 Q4: -12.0% Revenue growth, TTM YoY, FY24 Q1: -16.5% Revenue growth, TTM YoY, FY24 Q2: 26.9% Revenue growth, TTM YoY, FY24 Q3: 108.2% Revenue growth, TTM YoY, FY24 Q4: 137.4% Revenue growth, TTM YoY, FY25 Q1: 203.2% Revenue growth, TTM YoY, FY25 Q2: 366.8% Revenue growth, TTM YoY, FY25 Q3: 96.8% Revenue growth, TTM YoY, FY25 Q4: 144.6% Revenue growth, TTM YoY, FY26 Q1: 131.1% Revenue growth, TTM YoY, FY26 Q2: 948.3% 948.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -84.2%
FY23 Q4 -12.0%
FY24 Q1 -16.5%
FY24 Q2 26.9%
FY24 Q3 108.2%
FY24 Q4 137.4%
FY25 Q1 203.2%
FY25 Q2 366.8%
FY25 Q3 96.8%
FY25 Q4 144.6%
FY26 Q1 131.1%
FY26 Q2 948.3%
Operating margin (TTM) Meiragtx Holdings plc
-3000% -2000% -1000% 0% 1000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -2008.7% Operating margin (TTM), FY23 Q4: -977.8% Operating margin (TTM), FY24 Q1: -1336.3% Operating margin (TTM), FY24 Q2: -2083.2% Operating margin (TTM), FY24 Q3: -1267.0% Operating margin (TTM), FY24 Q4: -493.4% Operating margin (TTM), FY25 Q1: -460.9% Operating margin (TTM), FY25 Q2: -416.5% Operating margin (TTM), FY25 Q3: -597.9% Operating margin (TTM), FY25 Q4: -130.2% Operating margin (TTM), FY26 Q1: -131.9% Operating margin (TTM), FY26 Q2: 46.3% 46.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -2008.7%
FY23 Q4 -977.8%
FY24 Q1 -1336.3%
FY24 Q2 -2083.2%
FY24 Q3 -1267.0%
FY24 Q4 -493.4%
FY25 Q1 -460.9%
FY25 Q2 -416.5%
FY25 Q3 -597.9%
FY25 Q4 -130.2%
FY26 Q1 -131.9%
FY26 Q2 46.3%
FCF margin (TTM) Meiragtx Holdings plc
-2000% -1500% -1000% -500% 0% 500% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -1984.2% FCF margin (TTM), FY23 Q4: -895.6% FCF margin (TTM), FY24 Q1: -1036.6% FCF margin (TTM), FY24 Q2: -1289.8% FCF margin (TTM), FY24 Q3: -736.1% FCF margin (TTM), FY24 Q4: -328.9% FCF margin (TTM), FY25 Q1: -317.5% FCF margin (TTM), FY25 Q2: -353.3% FCF margin (TTM), FY25 Q3: -441.5% FCF margin (TTM), FY25 Q4: -61.7% FCF margin (TTM), FY26 Q1: 5.2% FCF margin (TTM), FY26 Q2: 2.6% 2.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -1984.2%
FY23 Q4 -895.6%
FY24 Q1 -1036.6%
FY24 Q2 -1289.8%
FY24 Q3 -736.1%
FY24 Q4 -328.9%
FY25 Q1 -317.5%
FY25 Q2 -353.3%
FY25 Q3 -441.5%
FY25 Q4 -61.7%
FY26 Q1 5.2%
FY26 Q2 2.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 13 16 38 16 14 33 81 398
EBITDA −56 −58 −65 −108 −123 −151 −93 196
Operating income −58 −63 −73 −116 −137 −164 −106 184
Net income −55 −58 −80 −130 −84 −148 −114 79
Diluted EPS −$1.65 −$1.54 −$1.80 −$2.87 −$1.49 −$2.12 −$1.42 $0.94
Growth (year on year)
Revenue — +17.1% +142.2% −57.8% −12.0% +137.4% +144.6% +948.3%
Margins
EBITDA margin −421.5% −375.1% −172.1% −676.1% −879.9% −454.9% −114.8% 49.3%
Operating margin −438.4% −401.9% −193.0% −730.9% −977.8% −493.4% −130.2% 46.3%
Net margin −411.9% −372.6% −211.0% −814.2% −599.5% −444.1% −140.3% 19.9%
Free-cash-flow margin 83.2% −545.5% −150.9% −741.6% −895.6% −328.9% −61.7% 2.6%
Cash flow
Cash from operations 20 −64 −11 −73 −105 −104 −46 14
Capital spending 9 21 46 45 20 5 4 3
Free cash flow 11 −85 −57 −118 −126 −109 −50 10
Stock-based pay 16 18 21 29 28 25 22 19
Free cash flow after stock pay −5 −103 −78 −147 −153 −135 −72 −9
Balance sheet
Cash 227 210 138 116 130 104 66 143
Total debt 0 0 1 71 72 73 74 100
Net debt (negative = net cash) −227 −210 −137 −44 −57 −30 8 −43
Diluted shares 33m 38m 44m 45m 56m 70m 80m 84m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $396m
Short-term assets $218mLonger-term assets $178m
What it owes, and who funded it · $396m
Short-term liabilities $58mLonger-term liabilities $123mShareholders' equity $216m
  • Short-term assets cover short-term liabilities $218m of assets due within a year against $58m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $218m short-term assets against $123m of longer-dated liabilities.
  • More cash than debt $143m of cash against $100m of debt.
  • Debt below 40% of shareholders' equity Debt is 46% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $14m of operating cash flow against $100m of debt.
  • Operating profit covers interest at least five times over Operating income of $184m against $12m of interest.

From Meiragtx Holdings plc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+8.6%
year over year
R&D spending
38.5%
of revenue
Days sales outstanding
15 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated MGTX MNKD SVA NVAX PHAR ARDX Median
Revenue, last 12 months $398m $394m $386m $414m $376m $451m $56m
Revenue growth, last 12 months 948.3% 30.5% 6.8% −61.6% 26.6% 16.8% 12.6%
Revenue growth, 3-year average 296.0% 35.5% 66.1% −36.3% — 75.9% 13.7%
Revenue growth, latest quarter >999% 42.9% — −76.3% — 23.8% 10.2%
Gross margin — 89.8% 67.9% 78.6% 87.9% 94.4% 82.9%
Operating margin 46.3% 2.3% −127.0% −56.6% 6.9% −7.9% −189.4%
Operating margin, 3-year average −817.8% 14.4% −3.3% −17.9% — −15.5% −363.5%
Net margin 19.9% −11.1% −15.5% −59.9% 0.8% −12.4% −169.8%
Cash from operations / revenue 3.4% −2.0% −132.7% −8.9% 14.5% −3.8% −168.0%
Free-cash-flow margin 2.6% −4.6% −145.4% −10.2% 14.3% −4.0% −162.4%
Free-cash-flow margin, 3-year average −546.8% 4.1% −14.0% −23.8% — −19.7% −310.0%
Stock pay / revenue 4.8% 7.1% 0.0% 7.8% 3.7% 12.1% 20.0%
Change in share count 8.6% 6.1% 0.0% 1.2% −4.9% 2.9% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 948.3% 12.6% 12 of 172
Change in growth rate Growth +817.2pp -0.1pp 6 of 172
Operating margin Profitability 46.3% -189.4% 5 of 175
Net margin Profitability 19.9% -157.3% 25 of 180
Free-cash-flow margin Cash generation 2.6% -145.4% 39 of 176
Stock pay as % of revenue Cash generation 4.8% 19.2% 33 of 179
Long-term debt as % of assets Balance sheet 25.2% 20.6% 47 of 78
Change in share count Balance sheet 8.6% 7.9% 85 of 156
Days sales outstanding Balance sheet 15 days 75 days 10 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $75M 92.1% —
Related Party Service Revenue $6.4M 7.9% ▼ 80.8%

From Meiragtx Holdings plc's 10-K filed March 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.1B
Institutions reporting
156
Shares held vs prior quarter
▲ 17.5%
Positions opened / closed
37 / 12

Top buyers and sellers, Q2 2026: 118 institutions bought and 34 sold ; the biggest buyer was Rubric Capital Management LP (+2.1M shares) and the biggest seller Prosight Management, LP (−2.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sanofi $165M 12.2M 15.4% 0.0%
Perceptive Advisors LLC $146M 10.8M 13.6% ▲ 4.5%
Rubric Capital Management LP $123M 9.1M 11.5% ▲ 30.0%
Johnson & Johnson $89.7M 6.6M 8.4% 0.0%
Blackrock, Inc. $64.3M 4.8M 6.0% ▲ 50.2%
Adage Capital Partners Gp, L.L.C. $59.4M 4.4M 5.6% ▲ 10.0%
Opaleye Management Inc. $48M 3.5M 4.5% ▲ 67.2%
Millennium Management LLC $40.1M 3.0M 3.8% ▼ 14.3%
683 Capital Management, LLC $31.1M 2.3M 2.9% ▼ 6.1%
Woodline Partners LP $20.3M 1.5M 1.9% ▲ 399.5%
State Street Corp $18.8M 1.4M 1.8% ▲ 84.9%
Morgan Stanley $17.7M 1.3M 1.7% ▼ 17.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Meiragtx Holdings plc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $4.7M 10 trades by 3 insiders · 100% under pre-set plans
Net ▼ $4.7M net selling
Insider Date Trade Shares Price Value
Giroux Richard CFO & COO October 20, 2026 Sell pre-set plan 56,000 $9.95 $557,200
Naylor Stuart CHIEF SCI OFCR, OPHTHALMOLOGY October 6, 2026 Sell pre-set plan 27,659 $10.64 $294,292
Forbes Alexandria PRESIDENT & CEO August 18, 2026 Sell pre-set plan 62,000 $13.86 $859,320
Giroux Richard CFO & COO July 21, 2026 Sell pre-set plan 56,000 $12.51 $700,560
Naylor Stuart CHIEF SCI OFCR, OPHTHALMOLOGY July 7, 2026 Sell pre-set plan 2,547 $13.86 $35,301
Naylor Stuart CHIEF SCI OFCR, OPHTHALMOLOGY July 7, 2026 Sell pre-set plan 25,112 $14.90 $374,169
Forbes Alexandria PRESIDENT & CEO May 19, 2026 Sell pre-set plan 62,000 $9.17 $568,540
Giroux Richard CFO & COO April 21, 2026 Sell pre-set plan 56,000 $10.22 $572,320
Naylor Stuart CHIEF DEV. OFFICER April 7, 2026 Sell pre-set plan 27,661 $9.36 $258,907
Forbes Alexandria PRESIDENT & CEO March 24, 2026 Sell pre-set plan 62,000 $7.41 $459,420

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • March 26, 2026
  • November 13, 2025
  • August 14, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Meiragtx Holdings plc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Meiragtx Holdings plc in brief

What does Meiragtx Holdings plc do?
Meiragtx Holdings plc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Meiragtx Holdings plc's stock ticker?
Meiragtx Holdings plc trades under the ticker MGTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Meiragtx Holdings plc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Meiragtx Holdings plc reported revenue of $398M, 948.3% higher than a year earlier, according to its SEC filings.
What is Meiragtx Holdings plc's free cash flow?
Meiragtx Holdings plc's free-cash-flow margin is 2.6% of revenue over the trailing twelve months, ranking 39 of the 176 biotechnology companies we cover.
Who are Meiragtx Holdings plc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Sanofi, Perceptive Advisors LLC and Rubric Capital Management LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Meiragtx Holdings plc's market cap?
On November 2, 2026, Meiragtx Holdings plc's market capitalisation was about $786M, with a price-to-earnings ratio of 9.9 and net debt of -$43.2M. Market figures come from third-party market data and may be delayed.
How much debt does Meiragtx Holdings plc have?
Meiragtx Holdings plc's debt-to-equity ratio is 46.3%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Meiragtx Holdings plc's competitors?
In our Biotechnology peer group, the companies closest to Meiragtx Holdings plc are Mannkind Corp, Sinovac Biotech LTD, Novavax Inc, Pharming Group N.V. and Ardelyx, Inc. The side-by-side comparison below sets their revenue, margins and growth against Meiragtx Holdings plc's.
Are insiders buying or selling Meiragtx Holdings plc stock?
Over the last 12 months, Meiragtx Holdings plc's directors and officers reported 0 open-market purchases and 10 sales on Form 4. The insider trading page charts every trade.
When is Meiragtx Holdings plc's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Meiragtx Holdings plc announces its own schedule.